Snips & notes | Biotech Message Board Posts

Biotech   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27137 of 32685  at  4/17/2019 9:11:10 AM  by


 In response to msg 27134 by  minxmrphd
view thread

Re: Snips & notes


$NDRA PR ENDRA Life Sciences Granted U.S. Patent for Determining Fractional Fat Content of Tissue

Credit Suisse Starts MacroGenics $MGNX at Outperform PT $29

$CASI: CASI Pharma signs a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics Limited (3.28)


Marker Therapeutics, Inc. ("Marker" or the "Company") previously communicated its understanding that Baylor College of Medicine ("BCM") clinicians would present initial clinical data with our MultiTAA T cell therapy in pancreatic cancer in the second quarter at the upcoming American Society of Clinical Oncology ("ASCO") meeting. BCM submitted its abstract to ASCO’s Trials in Progress ("TIP") track. As ASCO’s rules prohibit the inclusion of clinical outcome data in TIP abstract submissions, BCM’s clinical trial design abstract did not include any clinical data. The abstract was not accepted by ASCO.

Marker now expects to report more mature data from the BCM’s ongoing pancreatic study in the third quarter.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 179
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by